About: Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness
Creator	To, Dos Santos, Claudia Ka, Li Paula, Ana Mei, Shirley Stewart, Duncan Tsoporis, James Varkouhi, Amir Claudia, Santos Dos, Claudia Dossantos@unityhealth, Monteiro, Teixeira
Source	Medline; PMC
abstract	Critical illnesses including sepsis, acute respiratory distress syndromes, ischemic cardiovascular disorders and acute organ injuries are associated with high mortality, morbidity as well as significant health care system expenses. While these diverse conditions require different specific therapeutic approaches, mesenchymal stem/stromal cell (MSCs) are multipotent cells capable of self-renewal, tri-lineage differentiation with a broad range regenerative and immunomodulatory activities, making them attractive for the treatment of critical illness. The therapeutic effects of MSCs have been extensively investigated in several pre-clinical models of critical illness as well as in phase I and II clinical cell therapy trials with mixed results. Whilst these studies have demonstrated the therapeutic potential for MSC therapy in critical illness, optimization for clinical use is an ongoing challenge. MSCs can be readily genetically modified by application of different techniques and tools leading to overexpress or inhibit genes related to their immunomodulatory or regenerative functions. Here we will review recent approaches designed to enhance the therapeutic potential of MSCs with an emphasis on the technology used to generate genetically modified cells, target genes, target diseases and the implication of genetically modified MSCs in cell therapy for critical illness.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1007/s12015-020-10000-1
bibo:pmid	32671645
has license	no-cc
sha1sum (hex)	7c712b760940ec3143bd3145c855f0056020763e
schema:url	https://doi.org/10.1007/s12015-020-10000-1
resource representing a document's title	Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness
has PubMed Central identifier	PMC7363458
has PubMed identifier	32671645
schema:publication	Stem Cell Rev Rep
resource representing a document's body	covid:7c712b760940ec3143bd3145c855f0056020763e#body_text
is schema:about of	named entity 'MSC' named entity 'conditions' named entity 'range' named entity 'genes' named entity 'investigated' named entity 'respiratory distress' named entity 'critical illness' named entity 'Mesenchymal' named entity 'MULTIPOTENT' named entity 'REGENERATIVE' named entity 'TECHNIQUES' named entity 'TECHNOLOGY' named entity 'THEIR' named entity 'APPROACHES' named entity 'MSCs' named entity 'Critical' named entity 'immunomodulatory' named entity 'critical illness' named entity 'illnesses' named entity 'technology' named entity 'multipotent' named entity 'regenerative' named entity 'phase I' named entity 'mesenchymal' named entity 'studies' named entity 'Application' named entity 'genetically modified' named entity 'genetically modified' named entity 'mesenchymal' named entity 'critical illness' named entity 'MSCs' named entity 'cell therapy' named entity 'sepsis' named entity 'Mesenchymal' named entity 'optimization' named entity 'prokaryotic' named entity 'chemokines' named entity 'therapeutic effects' named entity 'AAVs' named entity 'HIF1' named entity 'permeability' named entity 'reduction of inflammation' named entity 'lipids' named entity 'MSCs' named entity 'MHC' named entity 'Homeostasis' named entity 'lentivirus' named entity 'MSCs' named entity 'overexpressing' named entity 'Minicircles' named entity 'organ' named entity 'anti-bacterial' named entity 'transfected' named entity 'plasmid DNA' named entity 'phagocytosis' named entity 'MSCs' named entity 'MSCs' named entity 'gene-editing technology' named entity 'AAV' named entity 'microRNA' named entity 'ALF' named entity 'CD105' named entity 'MSCs' named entity 'acute phase' named entity 'minicircles' named entity 'clinical trials' named entity 'anti-inflammatory' named entity 'ischemia' named entity 'MSCs' named entity 'ischemic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software